@article{ref1,
title="Effects of mizolastine and clemastine on actual driving and psychomotor performance in healthy volunteers",
journal="European journal of clinical pharmacology",
year="1994",
author="Vuurman, E. F. and Uiterwijk, M. M. and Rosenzweig, P. and O'Hanlon, J. F.",
volume="47",
number="3",
pages="253-259",
abstract="The acute effect of doses of mizolastine 5, 10, 20 and 40 mg, an active control (clemastine 2 mg) and placebo on actual car driving and psychomotor performance have been compared. Twenty four healthy volunteers were treated according to a double-blind, 6-way cross-over design. In the driving test, lasting about 1 h, lateral position control and speed were continuously measured; the psychomotor test battery, lasting 50 min, comprised critical flicker-fusion frequency, critical instability tracking, divided attention, memory search and choice reaction time, and vigilance studies; and mood changes and possible adverse-effects were rated on visual analogue scales. The results showed a dose-response relationship: mizolastine 40 and 20 mg impaired driving and psychomotor performance. The effect of mizolastine 40 mg on driving was strongly correlated with that of clemastine (r = 0.78) and was comparable to the effect of a blood ethanol level of 0.8 mg.ml-1. Mizolastine 5 mg and 10 mg did not have a significant effect on driving performance and psychomotor tests. It was concluded that at a 10 mg dose of mizolastine, the therapeutic dose, it could be considered a safe anti-histamine, although individual adverse reactions cannot be completely ruled out.<p /><p>Language: en</p>",
language="en",
issn="0031-6970",
doi="",
url="http://dx.doi.org/"
}